Table 1:
Characteristics of Included Trials
| Active 892 | Failed 225 | Completed 701 | “Good” Terminated 51 | p | |
|---|---|---|---|---|---|
| Cancer Type (%) | 0.0 02 | ||||
| Bladder | 159 (55.6] | 40 (14.0] | 82 (28.7] | 5 (1.7) | |
| Kidney | 197 (47.2] | 54 (12.9] | 150 (36.0] | 16 (3.8) | |
| Penile | 13 (72.2] | 2 (11.1] | 3 (16.7] | 0 (0.0) | |
| Prostate | 478 (44.8] | 123 (11.5] | 439 (41.1] | 28 (2.6) | |
| Testicular | 13 (37.1] | 4 (11.4] | 1 7 (48.6] | 1 (2.9) | |
| Ureter | 1 (33.3] | 1 (33.3] | 1 (33.3] | 0 (0.0) | |
| Urothelial | 31 (73.8] | 1 (2.4] | 9 (21.4] | 1 (2.4) | |
| Start Year (%) | <0.001 | ||||
| 2007 | 7 (4.7] | 25 (16.8] | 112 (75.2] | 5 (3.4) | |
| 2008 | 12 (9. 4] | 24 (18.9] | 84 (66.1] | 7 (5.5) | |
| 2009 | 12 (9.5] | 24 (19.0] | 84 (66.7] | 6 (4.8) | |
| 2010 | 14 (11.8] | 28 (23.5] | 75 (63.0] | 2 (1.7) | |
| 2011 | 21 (17.1] | 29 (23.6] | 64 (52.0] | 9 (7.3) | |
| 2012 | 33 (23.6] | 18 (12.9] | 82 (58.6] | 7 (5.0) | |
| 2013 | 38 (32.5] | 19 (16.2] | 54 (46.2] | 6 (5.1) | |
| 2014 | 69 (53.5] | 13 (10.1] | 45 (34.9] | 2 (1.6) | |
| 2015 | 71 (51.8] | 24 (17.5] | 41 (29.9] | 1 (0.7) | |
| 2016 | 122 (73.9] | 12 (7.3] | 28 (17.0] | 3 (1.8) | |
| 2017 | 194 (87.8] | 5 (2.3] | 20 (9.0] | 2 (0.9) | |
| 2018 | 229 (94.2] | 3 (1.2] | 11 (4.5] | 0 (0.0) | |
| 2019 | 70 (95.9] | 1 (1.4] | 1 (1.4] | 1 (1.4) | |
| Phase | |||||
| Phase 2 (%) | 704 (46.7) | 194 (12.9) | 567 (37.6) | 44 (2.9) | 0.064 |
| Phase 3 (%) | 188 (52.2) | 31 (8.6) | 134 (37.2) | 7 (1.9) | |
| Treatment (%) | <0.001 | ||||
| Drug/Supplement | 530 (42.4) | 160 (12.8) | 522 (41.8) | 37 (3.0) | |
| Device/Procedure | 64 (48.9) | 14 (10.7) | 50 (38.2) | 3 (2.3) | |
| Radiation | 136 (74.7) | 13 (7.1) | 31 (17.0) | 2 (1.1) | |
| Genetic/Biologic | 134 (54.7) | 31 (12.7) | 71 (29.0) | 9 (3.7) | |
| Behavioral | 11 (33.3) | 3 (9.1) | 19 (57.6) | 0 (0.0) | |
| Trial Countries (%) | <0.001 | ||||
| Non USA | 293 (48.1) | 51 (8.4) | 250 (41.1) | 15 (2.5) | |
| USA Only | 427 (46.4) | 156 (17.0) | 310 (33.7) | 27 (2.9) | |
| Both | 172 (50.6) | .8 (5.3) | 141 (41.5) | 9 (2.6) | |
| Sponsor | |||||
| Other | 617 (52.7) | 149 (12.7) | 373 (31.9) | 31 (2.6) | <0.001 |
| Industry (%) | 441 (44.5) | 123 (12.4) | 392 (39.6) | 35 (3.5) | 0.007 |
| NIH (%) | 163 (50.2) | 43 (13.2) | 112 (34.5) | 7 (2.2) | 0.494 |
| Other US Government (%) | 10 (55.6) | 2 (11.1) | 6 (33.3) | 0 (0.0) | 0.843 |
| Anticipated A ccrial (median (IQR)) | 90 (47–240) | 55 (34–108) | 63 (40–135) | 60 (40–163) | <0.001 |
| Trial Duration (median months (IQR)) | 41 (26–66) | 33 (21–51) | 50 (33–72) | 43 (27–60) | <0.001 |